Last reviewed · How we verify
A Randomized, Observer-Blinded, Parallel-Group, Active-Control, Phase 1/2 Trial of the Safety, Immunogenicity, and Tolerability of 20 µg, 60 µg, and 200 µg of Meningococcal Group B rLP2086 Vaccine in Healthy Adolescents Aged 10 to 12 Years
A study to assess the safety of an investigational meningitis vaccine in toddlers and their immune response to it.
Details
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 99 |
| Start date | 2006-10 |
| Completion | 2008-03 |
Conditions
- Healthy
Interventions
- MnB vaccine rLP8026
- MnB vaccine rLP8026
- MnB vaccine rLP8026
Primary outcomes
- Local and systemic reactions through 14 days post-injection; Vaccinations at 0,1,6 months — Vaccinations at 0,1,6 months
Countries
Australia